Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

6 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • 18F-AV-1451Registry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • FlortaucipirRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • FlortaucipirRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • FLORTAUCIPIR (18F)Registry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • FLORTAUCIPIR (18F)Registry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source
  • FlortaucipirRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source

Success Metrics

Active Trials
4(80%)

Phase Distribution

Not Applicable
1
20%
Phase 2
2
40%
Phase 2/3
2
40%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 2/3Combined phases
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Recruiting4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 2/3

Trials by Phase

Phase 22 (40.0%)
Phase 2/32 (40.0%)
N/A1 (20.0%)

Trials by Status

recruiting480%
unknown120%

Recent Activity

4 active trials
Showing 5 of 5
recruitingnot_applicable

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

NCT04150198
recruitingphase_2_3

TAP-TAU

SYF1c5fae45678f4b10adf4b8546551a7e4
recruitingphase_2

Tau PET imaging in cognitively normal elderly subjects: A twin approach

SYF9aa1f014d0674f7e916aa72a8ec5c294
recruitingphase_2_3

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

SYFeb262611f0e74d3c90f8503c45037c4a
unknownphase_2

Synaptic density and tau pathology in Alzheimer’s disease

SYFfd06e434df774e23bc5def87c83895aa

Clinical Trials (5)

Showing 5 of 5 trials
NCT04150198Not Applicable

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

Recruiting
SYF1c5fae45678f4b10adf4b8546551a7e4Phase 2/3

TAP-TAU

Recruiting
SYF9aa1f014d0674f7e916aa72a8ec5c294Phase 2

Tau PET imaging in cognitively normal elderly subjects: A twin approach

Recruiting
SYFeb262611f0e74d3c90f8503c45037c4aPhase 2/3

CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.

Recruiting
SYFfd06e434df774e23bc5def87c83895aaPhase 2

Synaptic density and tau pathology in Alzheimer’s disease

Unknown

All 5 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
5